MktsMarkets

MiNK Therapeutics, Inc.
NASDAQ: INKTKey statistics
INKT News
Stories mentioning INKT from around the web — every one is an open thread, so give it a like or add your take.
Loading news…
Financial statements
As filed, straight from the 10-Q — up to 19 years of history, free, with every line item chartable.
| Line item | Q1 '26Mar 31 | Q4 '25Dec 31 | Q3 '25Sep 30 | Q2 '25Jun 30 | Q1 '25Mar 31 | Q4 '24Dec 31 | Q3 '24Sep 30 | Q2 '24Jun 30 |
|---|---|---|---|---|---|---|---|---|
| Income Statement | ||||||||
| Revenue | ||||||||
| Cost of Goods Sold | ||||||||
| Gross Profit | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Expenses | ||||||||
| Research & Development | 1,204 | 1,513 | 1,143 | 1,839 | 1,262 | 1,406 | 541.00 | 1,840 |
| Sales General & Admin | ||||||||
| Total Operating Expenses | ||||||||
| Operating Income (Loss) | (2,882) | (2,705) | (3,184) | (4,052) | (2,701) | (2,502) | (1,885) | (3,071) |
| Interest Income | ||||||||
| Interest Expense | (4.00) | (29.00) | (25.00) | (27.00) | (29.00) | (29.00) | (28.00) | (26.00) |
| Other Expense | 59.00 | (7.00) | 241.00 | (186.00) | (80.00) | 331.00 | ||
| Pretax Income | ||||||||
| Tax Provision | ||||||||
| Net Income (Loss) | (2,742) | (2,601) | (2,888) | (4,238) | (2,767) | (2,463) | (1,807) | (2,702) |
| Earnings Per Share (Basic) | (0.57) | (0.61) | (0.65) | (1.06) | (0.70) | (0.65) | (0.46) | (0.73) |
| Earnings Per Share (Diluted) | (0.57) | (0.61) | (0.65) | (1.06) | (0.70) | (0.65) | (0.46) | (0.73) |
| Weighted Average Shares Outstanding (Basic) | 4,798 | 4,270 | 4,443 | 3,982 | 3,965 | 3,773 | 3,953 | 3,714 |
| Weighted Average Shares Outstanding (Diluted) | 4,798 | 4,270 | 4,443 | 3,982 | 3,965 | 3,773 | 3,953 | 3,714 |
Scroll the table sideways for older periods — the line-item column and the period header stay put. Hover a row and use the chart handle to plot it over the full history.
About INKT
MiNK Therapeutics, Inc. (NASDAQ: INKT) is a stock listed on the Nasdaq Stock Market under the ticker symbol INKT. It last traded at $10.84 (Oct 29, 2026, 2:52 PM ET), up 0.4% on the day. That gives MiNK Therapeutics a market capitalisation of $55.1M.
Over the past 52 weeks INKT has traded between $8.48 and $16.93.
For the quarter ended Mar 31, 2026 it reported a net loss of $2.7M.
| Quarter ended | Revenue | Net income |
|---|---|---|
| Mar 31, 2026 | — | -$2.7M |
| Dec 31, 2025 | — | -$2.6M |
| Sep 30, 2025 | — | -$2.9M |
| Jun 30, 2025 | — | -$4.2M |
From MiNK Therapeutics’s quarterly (10-Q) filings, in US dollars.
Take a break — play a market game
Seven free games built around the markets. No download, no sign-up: they run right here in your browser.
Latest News
Market news from around the web — every story is an open thread, so give it a like or add your take.
Loading news…